Actavis launches pain drug
Sep 20, 2013 (MarketLine via COMTEX) --
Actavis, Inc., a specialty pharmaceutical company, has launched Oxymorphone Hydrochloride Extended-release Tablets, 5mg, 10mg, 20mg, 30mg and 40mg.
Actavis' ANDA product is the generic equivalent to the previously marketed formulation of Endo Health Solutions' Opana ER, which was voluntarily withdrawn from sale in 2012.
Actavis previously received approval for, and is currently marketing, Oxymorphone Hydrochloride Extended-release Tablets 7.5 mg and 15 mg. Actavis is currently a defendant in a lawsuit filed by Endo alleging that Actavis' Oxymorphone Hydrochloride Extended-release product infringes certain of Endo's patents.
Opana ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time.
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To Technology News's Homepage ]